IMPORTANCE Traumatic brain injury (TBI) is a significant public health concern that affects individuals in all demographics. With increasing interest in the medical and public communities, understanding the inflammatory mechanisms that drive the pathologic and consequent cognitive outcomes can inform future research and clinical decisions for patients with TBI. or therapeutic studies that involved manipulation of the discussed mechanisms were considered for inclusion. The final list of selected studies was assembled based on novelty and direct relevance to the primary focus of this review.
Traumatic brain injury is a significant cause of mortality in children and young adults, and the incidence in older individuals has increased with the average life span. 4 Mild TBI (mTBI) is the most frequent type diagnosed, typically resulting in post-TBI survival. Traumatic brain injury is suspected to contribute to a variety of chronic degenerative processes, including chronic traumatic encephalopathy, Alzheimer disease, and Parkinson disease. 5 Traumatic brain injury is initiated by the application of mechanical force to the head, which can occur with or without loss of consciousness. This then triggers a series of cerebral events that depend in part on the nature and location of the injury. A major challenge associated with treating patients with TBI is the diverse pathologic and pathogenic mechanisms that become operational after injuries. For example, TBI often promotes disruption of blood-brain barrier (BBB) integrity and the neurovascular unit, which can result in vascular leakage, edema, hemorrhage, and hypoxia. Other pathologic mechanisms include cell death within the meninges and brain parenchyma, stretching and tearing of axonal fibers, and disruptions at the junctions between white and gray matter, stemming from rotational forces that cause shearing injuries. 6 All these primary pathologic mechanisms are accompanied by cellular and molecular cascades leading to inflammation and additional cell death. This review focuses on our current understanding of the sterile immune reaction to TBI and some clinical successes in treating patients with TBI. We searched articles in PubMed published between 1960 and August 1, 2014, using the following keywords: traumatic brain injury, sterile injury, inflammation, astrocytes, microglia, monocytes, macrophages, neutrophils, T cells, reactive oxygen species, alarmins, danger-associated molecular patterns, purinergic receptors, neuroprotection, and clinical trials. Clinical trials or therapeutic studies that involved manipulation of the discussed mechanisms were considered for inclusion. The final reference list was assembled based on novelty and direct relevance to the primary focus of this review.
Sterile Immune Reaction to TBI
Central nervous system (CNS) resident and peripherally derived inflammatory cells respond quickly to brain injuries and can even participate in the repair process. 7, 8 These responses are commonly referred to as sterile immune reactions. A previous study 9 found that the inflammatory gene expression profile is comparable between mTBI and severe TBI, suggesting a common response to both forms of injury. The acute cellular reaction to TBI includes astrocytes, microglia, monocytes or macrophages, neutrophils, and T cells, which are initially activated in part by purinergic receptor signaling. 10, 11 In the following paragraphs, we describe the inflammatory response to TBI in more detail, focusing specifically on traditional immune cell populations. Sterile immune reactions are at least initially designed to be beneficial but can become detrimental in certain situations.
Danger Signals
Pathogens can trigger innate immune activation via pathogenassociated molecular pattern molecules, which are conserved structures within a class of microbes recognized by Toll-like receptors or pathogen-recognition receptors. These innate signaling pathways allow plants and animals to respond quickly to invading microbes. However, it is now recognized that tissue damage in the absence of microbial infection can trigger inflammasome and innate immune activation through the release of damage-associated molecular pattern molecules (DAMPs), sometimes referred to as danger signals.
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Alarmins are endogenous DAMPs released by cells undergoing nonapoptotic death or by cells of the immune system. 13 Some examples of alarmins include HMGB1, S-100 proteins, adenosine triphosphate (ATP), uric acid, DNA or RNA, and interleukin 1α, among others. After TBI, alarmins are undoubtedly released, 14 and this triggers a sterile immune reaction designed to restore tissue homeostasis. However, the severity and duration of injury can foster maladaptive immune reactions that become injurious. A previous study 15 found that ATP release and detection via puringeric receptors elicit an acutely neuroprotective inflammatory response after mild cortical injury, but sustained immune activation may not always be beneficial. For example, therapeutic blockade of inflammasome activation reduced innate immune activation and severe TBI lesion size. 16 Thus, additional research is required to better understand the rules that govern pathogenic vs nonpathogenic innate immune reactions after DAMP signaling in the injured brain.
Purinergic Receptor Signaling
Purinergic receptors are an evolutionarily ancient family of transmembrane molecules that detect ATP, adenosine diphosphate (ADP), or adenosine. 10, 11 The receptors are divided into 2 basic classes based on whether they respond to adenosine (P1 receptors) or ATP or ADP (P2 receptors). Because ATP is a cellular source of energy, it is maintained at a high intracellular concentration during steady-state conditions. After tissue injury, ATP is released from damaged cells, which triggers an immune reaction via purinergic receptor signaling. This reaction can be amplified by pannexin and connexin hemichannels that pump ATP from healthy cells into the extracellular space. Sterile immune reactions generally subside as ATP is converted into adenosine through a 2-step reaction that involves ectonucleoside triphosphate diphosphohydrolase 1 (CD39) and ecto-5′-nucleotidase (CD73). Astrocytes and microglia each express at least one these ectoenzymes, 17, 18 allowing them to dampen ATP-mediated neuroinflammation.
Microglia
Microglia are highly dynamic CNS resident innate immune sentinels that originate from primitive myeloid progenitor cells during development. 19, 20 Microglia participate in a variety of homeostatic CNS functions, including synaptic plasticity and learning, 21 and are often the first responders to any inflammatory event that occurs within the parenchyma. 20 Microglia mediate neuron removal during development via release of reactive oxygen species (ROS) and can acquire a phagocytic phenotype without an inflammatory response. 20 Microglial expression of genes associated with neuro-number of surface and cytoplasmic receptors, and cumulative signaling through these receptors determines whether microglia remain in a ramified, sentinel state or take on various configurations as a result of activation. 23 In addition, microglia can sense a large repertoire of exogenous and endogenous signals, allowing for dynamic responses to sterile injuries and infectious agents that can be injurious or neuroprotective, depending on the context. 22 During CNS autoimmune disease, activated microglia phagocytose debris and downregulate cellular metabolism in contrast to disease-initiating, peripherally derived macrophages, which appear to play a more destructive role by promoting demyelination. 24 These data suggest that microglia are not inherently neurotoxic during development of a CNS autoimmune disease. After acute focal brain injury in rodents, microglia similarly appear to play a neuroprotective role. 15 Using 2-photon microscopy, we revealed that microglia respond within minutes of brain injury by extending processes to the glial limitans and circumscribing individual astrocytes, resembling a hexagonal honeycomb structure ( Figure 1A -E, Figure 2E and H, and Videos 1 and 2). This reaction was dependent on purinergic receptor signaling (P2X 4 and P2Y 12 ) and astrocytic ATPdependent ATP release via connexin hemichannels. In response to cell death (eg, astrocytic cell death in the glial limitans), microglia transformed into phagocytic cells that resembled jellyfish ( Figure 1A -E, Figure 2F and I, and Videos 1 and 2). Jellyfish microglia were highly mobile and often inserted themselves into the damaged glial limitans in place of dead astrocytes, connecting together to form a phagocytic barrier. This reaction was also dependent on purinergic receptor signaling (P2X 4 , P2Y 6 , P2Y 12 ) and connexin hemichannels. When these microglia responses were inhibited locally through blockade of purinergic receptor signaling or connexin hemichannels, the pathologic mechanisms observed after brain injury were more severe. One of the most notable changes was increased leakage of materials through the glial limitans into the brain parenchyma. These data suggest that microglia not only clean up debris from the injured brain but also help maintain glial limitans barrier integrity by sealing the gaps that result from dead or damaged astrocytes. Moreover, our data are consistent with previous studies [25] [26] [27] [28] that link microglia injury responses to ATP release and purinergic receptor signaling. Although it is conceivable that microglia responses become maladaptive over time or after exposure to different combinations of stimuli, 29 we propose that the acute role of microglia in the focally injured brain is neuroprotective.
Monocytes and Macrophages
Monocytes are a multipotent population of circulating bone marrowderived leukocytes capable of differentiating into macrophages or dendritic cells after invasion of an infected or injured tissue. 30 They are also known to participate in diverse functions, such as phagocytosis, cytokine or chemokine release, antigen presentation, immune modulation, and tissue repair. In the naive brain, there are also populations of specialized macrophages that reside in the meninges, choroid plexus, and perivascular spaces. 31 Their role in TBI pathogenesis is unknown. Another study 15 also found that meningeal macrophages are among the first cells to die after focal cortical injury and may serve as an early source of alarmins and ROS ( Figure 1A -C, Figure 2A and B, and Video 1). 
Neutrophils
Neutrophils are an abundant population of circulating leukocytes that are usually among the first responders to tissue injuries in the periphery and CNS. 37 Neutrophils are often viewed as a proinflammatory cell population but are known to play a vital role in wound healing through their involvement in phagocytosis, metalloproteinase release, and growth factor production. After tissue injury, neutrophils can help prepare the damaged environment for repair. Neutrophils are rapidly recruited to the CNS after TBI and enter through meningeal blood vessels and the choroid plexus. 15, 32, 38, 39 They can also facilitate the recruitment of monocytes. 37 A previous study 40 focused on sterile injury of the liver found that ATP released from the damaged tissue induced inflammasome activation in a P2X 7 Rdependent manner. This activation in turn promoted rapid recruitment of neutrophils through release of chemoattractants (CXCL1 and CXCL2) and formyl peptides that guided these cells to the site of injury. After focal TBI, we observed that neutrophils are similarly recruited in a P2X 7 R-dependent manner and arrive within 1 hour of injury ( Figure 2C ). 15 Visualization of cellular dynamics and localization by 2-photon microscopy revealed that neutrophils localized primarily to the damaged meninges (instead of the parenchyma), where they swarmed the area and interacted with dead cells. Antagonism of this response by blocking P2X 7 R signaling increased the amount of cell death in the meninges, suggesting a protective role for neutrophils in the meningeal space after focal cortical injury. Neutrophils are not always neuroprotective and have the capacity to break down the BBB by releasing metalloproteinases, proteases, tumor necrosis factor α, and ROS. Inflammatory mediators released after brain injury can facilitate this process by inducing a hyperactivated state that allows neutrophils to breach the BBB and enter the CNS. 41 On arrival, neutrophils have the potential to induce neuronal cell death using the same soluble mediators that break down the BBB. 42 A previous study 43 revealed that neutrophils are the most abundant cell population in circulation after TBI and cause increased expression of oxidative enzymes indicative of activation. Depletion of neutrophils with anti-Gr-1 antibodies after controlled cortical impact in rodents reduced edema, microglia and macrophage activation, and TBI lesion size, but did not affect vascular leakage at 24 to 48 hours after injury. 44 These data reveal that neutrophils can be pathogenic after open-skull cortical impact. However, the contribution of neutrophils to a CNS lesion may depend on their precise localization and state of activation. Open-skull controlled cortical impact is highly disruptive to meningeal architecture and likely favors neutrophil recruitment to the heavily damaged brain parenchyma. These findings contrast with mild closed-skull cortical injury, which maintains meningeal architecture and fosters a more selective pattern of neutrophil recruitment. 15 To definitively establish the contribution of neutrophils to TBI pathogenesis, these cells should be evaluated in many different models of brain injury. It is conceivable that their contribution will differ based on the nature of the injury. 
Clinical Review & Education Clinical Implications of Basic Neuroscience Research
Traumatic Brain Injury dress the role of T cells in TBI, a previous study 48 examined the response to closed-skull head injury in RAG1 knockout mice that lack mature T and B cells. No difference in any pathologic or neurologic parameters was observed between wild-type and RAG1-deficient mice for up to 1 week. These data suggest that T cells play no role in early TBI pathogenesis. Additional studies are required to determine whether T cells actively participate in chronic TBI lesions (beyond 1 week) and/or the reparative process.
Therapeutic Modulation of TBI Pathogenesis
The pathogenesis of TBI is complex as reflected by the number of clinical trials that have failed to improve outcomes in humans.
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The many reasons for these failures have been discussed in other reviews. 49, 50 Rather than focus on the reasons for prior failures, we instead briefly discuss some successes that pertain to mechanisms of pathogenesis and inflammation covered in this review. The concept of free radical-mediated damage of CNS tissue after injury has existed for several decades.
51,52 Administration of effective antioxidants has the potential to significantly limit the spread of damage and inflammation if given soon after brain injury. In animal models, a number of previous studies 53, 54 have yielded promising results with antioxidants that neutralize ROS. For example, intravenous administration of the small-molecule free radical scavenger edaravone at 2 and 12 hours after weight drop-induced TBI resulted in significantly reduced inflammation, edema, BBB breakdown, lesion size, and neurologic deficits. 53 Inhibition of NADPH oxidase complex assembly with apocynin also reduced ROS production, BBB breakdown, and neuronal cell death after weight dropinduced TBI. 54 The only caveat of this study was that the apocynin was injected intraperitoneally 15 minutes before injury. Nevertheless, the favorable outcome implicates NADPH oxidase as a potential source of ROS after brain injury. Using a new model of mild cortical injury, we found that transcranial administration of the antioxidant glutathione at 15 minutes meningeal cell death by approximately 50%. These data indicate that ROS are a primary inducer of cell death and inflammation after focal brain injury and that an antioxidant can have a major effect on lesion expansion if given early. The advantage of passing a neuroprotective compound directly through the skull bone (transcranial delivery) is that a high local drug concentration can be achieved in the CNS with a limited off-target effect on the periphery.
Previous studies 55, 56 have supported antioxidants as neuroprotective agents in rats and humans, revealing that administration of N-acetylcysteine reduces brain damage and improves recovery after TBI. N-acetylcysteine is the cellular precursor to glutathione. A randomized, double-blind, placebo-controlled clinical trial 55 was performed to assess efficacy in members of the military who experienced a mTBI that resulted from blast exposure. Patients who received N-acetylcysteine within 24 hours had significantly improved recovery during a 7-day period when compared with a placebo control group. These findings were corroborated in 2 different rodent models of TBI (weight drop and fluid percussion), which revealed that N-acetylcysteine reversed the behavioral deficits associated with mTBI and moderate TBI. 56 Further studies are needed to determine whether this promising neuroprotective intervention will be efficacious in patients with diverse types of brain injury.
Many clinical trials have been completed or are under way to assess the role of excitotoxic mechanisms in TBI pathogenesis. 49, 50 With the exception of amantadine, all drugs in this class tested to date have not been effective in promoting recovery in patients with TBI. Amantadine is thought to act as an N-methyl-D-aspartate receptor antagonist and an indirect dopamine agonist. When patients with TBI were treated during a 4-week period beginning 4 to 16 weeks after injury, amantadine improved recovery relative to the placebo control. The mechanism underlying this positive effect remains unclear. Prevention of N-methyl-D-aspartate receptormediated excitatory damage seems unlikely given that the drug was administered a month or more after the initial injury.
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Manipulation of purinergic receptor signaling is another therapeutic approach worth considering. Use of specific purinergic receptor agonists and antagonists should allow therapeutic amelioration of different TBI lesion parameters. A previous study 15 found that microglia responses after mTBI were dependent on P2X 4 , P2Y 6 , and P2Y 12 receptors, whereas P2X 7 R signaling was necessary for neutrophil recruitment. It might be possible to promote neuroprotective inflammatory responses through therapeutic agonism of these pathways after brain injury. The challenge, however, with purinergic receptor manipulation is that specific receptors are often expressed on multiple cell populations. A purinergic receptor agonist or antagonist will likely affect multiple cell populations simultaneously. As an example, a previous 58 study found that P2X 7 R localized to astrocytic end feet and antagonism of this receptor reduced astrocyte activation, cerebral edema, and neurobehavioral abnormalities after controlled cortical impact-induced TBI. A similar protective effect was obtained by blocking P2X 7 R after spinal cord injury, which was linked to receptor expression on spinal cord neurons. 59 However, P2X 7 R is also expressed on inflammatory cells, and a previous study 15 found that antagonism of this pathway increased meningeal cell death after mTBI, likely due to diminished neutrophil recruitment. Thus, purinergic receptor modulation can positively affect one CNS environment and negatively affect another. It will therefore be important in future studies to map out the exact contributions of specific purinergic receptors to different TBI lesion parameters before deciding which (if any) are best to target therapeutically in patients.
Discussion
The pathogenesis of TBI is initially induced by a mechanical injury that sets into motion a complex secondary reaction mediated by ROS, purines, calcium ions, excitatory amino acids, and DAMPs, among others. This pathogenesis in turn triggers a robust sterile immune reaction that consists of CNS resident and peripherally recruited inflammatory cells. The response is designed to be neuroprotective and promote wound healing but can become maladaptive over time, especially if the lesion remains active for weeks. Among the earliest soluble mediators are ROS and purines. Both are released within minutes of brain injury and initiate an inflammatory cascade. Even after mild focal cortical injury, ROS can damage the glial limitans that separate the meninges and parenchyma, which results in lesion expansion within brain tissue. Vascular damage and leakage represent another early hallmark of TBI pathogenesis that can foster edema, hypoxia, and tissue destruction. After brain injury, the innate immune system quickly mobilizes in response to purines and alarmins, and astrocytes help orchestrate this response by serving as inflammatory amplifiers. Within minutes, resident microglia are among the first to react by fortifying CNS barriers and participating in phagocytic cleanup. Neutrophils and monocytes arrive shortly thereafter and preferentially survey injured meningeal spaces if the CNS architecture remains intact. Focal brain injury elicits an anatomically partitioned immune reaction (at least acutely) with myelomonocytic cells tending to the damaged meninges and microglia responding within the parenchyma. Eventually, myelomonocytic cells can enter the damaged brain, and studies [40] [41] [42] have found that their presence there is sometimes neurotoxic. However, sterile immune reactions are not inherently neurotoxic and are usually elicited to prepare a damaged tissue for wound healing. Thus, the entire contribution of immune cell subsets to TBI lesions needs to be considered before targeted therapeutic interventions can be intelligently designed. Another important variable is time. The exact contribution of immune cells to a TBI lesion may in fact shift over time. For example, an initially neuroprotective immune response may become maladaptive as secondary inducers of tissue destruction diversify.
Although TBI has proven difficult to treat, promising interventions lie on the horizon. Given the importance of ROS in TBI pathogenesis and the success with N-acetylcysteine in patients with mTBI, clinical pursuit of antioxidant therapy seems warranted. The likely key to success is early treatment with antioxidants so that TBI lesion expansion and subsequent inflammation can be stopped as soon as they are initiated. Because TBI lesions begin to expand within hours of injury, development of strategies to rapidly preserve brain tissue is paramount. The kinetics of lesion expansion must be similarly considered when attempting to manipulate purinergic and excitatory neurotransmitter pathways, which engage rapidly after in-
